FREZENT is a preclinical-stage oncology therapeutics company based in New York. We are developing bispecific antibodies and antibody-drug conjugates aimed at targeting dormant cancer cells that may lead to cancer recurrence.
Dormant cancer cells are small residual portions of a tumor that were not completely eliminated by treatment. These cells can remain undetectable in the body for a period of time, but eventually, they can transform back into fast-growing tumors.
FREZENT is working on a novel cancer treatment to block the reactivation of dormant cancer cells. To achieve this, we are developing therapeutics that neutralize the metabolic factors supplied by the tumor microenvironment, which support dormant cancer cells. In their dormant state, cancer cells rely on these external supplies, and blocking them will effectively starve the cancer cells and induce cell death.
Join us in our mission to ensure a future where long-lasting remission is a reality for all cancer patients.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 7 Pennsylvania Plaza, New York,ny 10001,united States
- Industry
- Biotechnology
- Website
- http://www.frezent.com
- HQ
- New York, NY
Frezent Biological Solutions Questions
Frezent Biological Solutions's website is http://www.frezent.com
Frezent Biological Solutions's LinkedIn profile is https://www.linkedin.com/company/frezent-biological-solutions
Frezent Biological Solutions has
10 employees.
View email and phone details for 10
employees at Frezent Biological Solutions.
Frezent Biological Solutions's industry is
Biotechnology
Frezent Biological Solutions's top competitors are
Global Source Ventures, Llc,
Senex Therapeutics,
Collage Bio,
Stratum Biosciences,
Nest Catalyst Ventures,
Switchback Therapeutics,
Genomic Expression Inc,
Market Modelers®,
Aveta.life,
Xias Bio.
Frezent Biological Solutions's categories are Biotechnology
Frezent Biological Solutions's founding year is 2017
